Stage III Solid Tumors, Stage IV Solid Tumors
Conditions
Brief summary
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Interventions
DIAGNOSTIC_TESTComprehensive liquid molecular panel test
Lab test
OTHEREORTC QLQ-30
Quality of life questionnaire
Sponsors
Guardant Health, Inc.
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have given informed consent in accordance with the methods and procedures of this study * Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care * Patients who have not received treatment related to his/her cancer * Patients who are willing to sign a release of medical records to the research team * Male and female patients ≥18 years of age * Patients under oncology care * Sufficient clinical status for collection of blood sample within usual care
Exclusion criteria
* Patients considered minors in the jurisdiction where the protocol is conducted * Patients who are prisoners and pregnant women * Patients who cannot provide consent and did not sign a power of attorney
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (QLQ-C30) | 2 years | The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions. The scaling of items is 1 (Not at all) to 4 (Very much), 1 (Very poor) to 7 (Excellent). The higher the score the better the quality of life. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare the proportion of enrolling in clinical trials | 2 years | To compare the proportion of enrolling in clinical trials between cancers patients who received the CLMT versus cancer patients with no CLMT. |
Countries
United States
Contacts
Primary ContactMihran H Shirinian, MD
Backup ContactLily Villalobos, MHA
Outcome results
None listed